These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 11398877

  • 1. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V, Greek Lung Cancer Cooperative Group.
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
    Kelly K, Lovato L, Bunn PA, Livingston RB, Zangmeister J, Taylor SA, Roychowdhury D, Crowley JJ, Gandara DR, Southwest Oncology Group.
    Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808
    [Abstract] [Full Text] [Related]

  • 3. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 4. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A.
    J Clin Oncol; 2006 May 01; 24(13):2038-43. PubMed ID: 16648503
    [Abstract] [Full Text] [Related]

  • 5. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC.
    J Clin Oncol; 1994 Oct 01; 12(10):2022-34. PubMed ID: 7931470
    [Abstract] [Full Text] [Related]

  • 6. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
    Dowlati A, Crosby L, Remick SC, Makkar V, Levitan N.
    Lung Cancer; 2001 May 01; 32(2):155-62. PubMed ID: 11325486
    [Abstract] [Full Text] [Related]

  • 7. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
    Mavroudis D, Veslemes M, Kouroussis Ch, Tzanakis N, Ferdoutsis E, Toumbis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, Souglakos J, Magkanas E, Samonis G, Georgoulias V, Hellenic Oncology Research Group.
    Lung Cancer; 2002 Oct 01; 38(1):59-63. PubMed ID: 12367794
    [Abstract] [Full Text] [Related]

  • 8. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S, Agelidou A, Androulakis N, Tsaroucha E, Kouroussis Ch, Agelidou M, Karvounis N, Veslemes M, Christophylakis Ch, Argyraki A, Geroyianni A, Georgoulias V.
    Lung Cancer; 2006 Jul 01; 53(1):59-65. PubMed ID: 16716447
    [Abstract] [Full Text] [Related]

  • 9. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlakou G, Tselepatiotis E, Nikolakopoulos J, Georgoulias V.
    Clin Lung Cancer; 2005 Nov 01; 7(3):183-9. PubMed ID: 16354313
    [Abstract] [Full Text] [Related]

  • 10. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA, Herndon JE, Hollis DR, Ellerton J, Langleben A, Richards F, Green MR.
    J Clin Oncol; 1995 Aug 01; 13(8):1871-9. PubMed ID: 7636529
    [Abstract] [Full Text] [Related]

  • 11. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK.
    Cancer; 1998 Jan 15; 82(2):301-8. PubMed ID: 9445186
    [Abstract] [Full Text] [Related]

  • 12. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
    Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR, Cancer and Leukemia Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3752-9. PubMed ID: 15923572
    [Abstract] [Full Text] [Related]

  • 13. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
    Oh IJ, Kim KS, Park CK, Kim YC, Lee KH, Jeong JH, Kim SY, Lee JE, Shin KC, Jang TW, Lee HK, Lee KY, Lee SY.
    BMC Cancer; 2016 Aug 26; 16(1):690. PubMed ID: 27566413
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, Thomas M, Greco FA.
    J Clin Oncol; 1997 Dec 26; 15(12):3464-70. PubMed ID: 9396399
    [Abstract] [Full Text] [Related]

  • 15. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R.
    Cancer; 2003 May 15; 97(10):2498-503. PubMed ID: 12733149
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec 15; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 17. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K, Nishiwaki Y, Sugiura T, Noda K, Mori K, Kawahara M, Negoro S, Watanabe K, Imamura F, Tamura T, Saijo N.
    Clin Cancer Res; 2005 Aug 01; 11(15):5534-8. PubMed ID: 16061870
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.
    Bunn PA, Kelly K.
    Semin Oncol; 1996 Dec 01; 23(6 Suppl 16):11-5. PubMed ID: 9007114
    [Abstract] [Full Text] [Related]

  • 19. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
    Bunn PA, Kelly K.
    Semin Oncol; 1997 Aug 01; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
    [Abstract] [Full Text] [Related]

  • 20. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
    Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, Shi A, Jiang W, Xu Y, Zhou Z, Wang W, Chen D, Hui Z, Lv J, Zhang H, Feng Q, Xiao Z, Wang X, Liu L, Zhang T, Du L, Chen W, Shyr Y, Yin W, Li J, He J, Wang L.
    Ann Oncol; 2017 Apr 01; 28(4):777-783. PubMed ID: 28137739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.